CN105073739B - 用于制备吲唑衍生物的中间体及其制备方法 - Google Patents

用于制备吲唑衍生物的中间体及其制备方法 Download PDF

Info

Publication number
CN105073739B
CN105073739B CN201480009452.4A CN201480009452A CN105073739B CN 105073739 B CN105073739 B CN 105073739B CN 201480009452 A CN201480009452 A CN 201480009452A CN 105073739 B CN105073739 B CN 105073739B
Authority
CN
China
Prior art keywords
compound
alkali
formula
raney
catalyst
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480009452.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073739A (zh
Inventor
T.C.伊里
B.P.哈彻
D.朱恩格斯特
S.R.斯潘塞
P.J.施滕格尔
D.J.沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN105073739A publication Critical patent/CN105073739A/zh
Application granted granted Critical
Publication of CN105073739B publication Critical patent/CN105073739B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480009452.4A 2013-02-27 2014-02-27 用于制备吲唑衍生物的中间体及其制备方法 Active CN105073739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770031P 2013-02-27 2013-02-27
US61/770,031 2013-02-27
PCT/US2014/019039 WO2014134313A1 (en) 2013-02-27 2014-02-27 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
CN105073739A CN105073739A (zh) 2015-11-18
CN105073739B true CN105073739B (zh) 2017-10-24

Family

ID=50288305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480009452.4A Active CN105073739B (zh) 2013-02-27 2014-02-27 用于制备吲唑衍生物的中间体及其制备方法

Country Status (5)

Country Link
US (1) US9790206B2 (enExample)
EP (1) EP2961744B1 (enExample)
JP (1) JP6433922B2 (enExample)
CN (1) CN105073739B (enExample)
WO (1) WO2014134313A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
AU2007210073B2 (en) * 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
JP2009531445A (ja) * 2006-03-29 2009-09-03 アレイ バイオファーマ、インコーポレイテッド ｐ３８インヒビターおよびその使用方法
TWI365185B (en) * 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
CN102510862A (zh) * 2009-07-14 2012-06-20 阿尔巴尼分子研究公司 5-ht3受体调节剂、其制备方法和用途

Also Published As

Publication number Publication date
JP6433922B2 (ja) 2018-12-05
US9790206B2 (en) 2017-10-17
WO2014134313A1 (en) 2014-09-04
US20160002210A1 (en) 2016-01-07
EP2961744A1 (en) 2016-01-06
EP2961744B1 (en) 2017-06-28
JP2016516670A (ja) 2016-06-09
CN105073739A (zh) 2015-11-18

Similar Documents

Publication Publication Date Title
JP5587324B2 (ja) キノリニルオキシジフェニルシクロプロパンジカルボキサミドの製造
EP2411398B1 (en) Method for manufacturing a boronic acid ester compound
CN105384741A (zh) 一种细胞周期调节蛋白依赖性激酶抑制剂的盐及其制备方法
CA2649245A1 (en) Process for the preparation of cinacalcet base
JP6644685B2 (ja) ポマリドミドの調製およびその精製のための改善された方法
CN105073739B (zh) 用于制备吲唑衍生物的中间体及其制备方法
CN109485638A (zh) 一种奥希替尼中间体的制备方法
WO2015111085A2 (en) Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof
CN115448848A (zh) 一种抗真菌化合物制备方法
CN101759601A (zh) 利用过渡金属配合物制备手性α-非天然氨基酸的方法
CN1345300A (zh) 杀虫剂中间体的制备方法
EP3141543A1 (en) New vortioxetine intermediate and synthesis process thereof
CN105924431B (zh) 化合物克唑替尼的合成工艺
CN103159747A (zh) 一种二对甲苯磺酸拉帕替尼的合成方法
CN114230568B (zh) 一种her2小分子抑制剂图卡替尼的制备方法
CN105801559B (zh) 4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯甲酸乙酯的制备方法
CN113402502B (zh) 一种parp抑制剂中间体制备的物料组合体系
CN114805170A (zh) 一种新型赛洛多辛手性中间体的制备方法
WO2022011948A1 (zh) 制备沃替西汀的方法
CN110204490B (zh) 一种二取代4-氯喹啉-3-甲腈衍生物及伯舒替尼的制备方法
CN107739328A (zh) 用于合成巴瑞替尼的关键中间体1的制备方法
KR101004133B1 (ko) 아세틸렌 화합물의 제조방법
JP2012036104A (ja) カンデサルタンシレキセチルの製造法
CN110577520B (zh) 一种6-硝基-4-取代氨基喹唑啉衍生物的制备方法
CN120208971A (zh) 一种jak抑制剂中间体的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant